BioWorld

Feb. 23, 2010

Viamet, Novartis Fund Targeting Metalloenzymes in $200M Deal

Viamet Pharmaceuticals Inc. signed a deal worth more than $200 million with the Novartis Option Fund to discover and develop metalloenzyme inhibitors of interest to the Swiss drugmaker. (BioWorld Today) Read More

FDA Raises Endpoint Concerns in Study of Salix Liver Drug

Blocking Backup Pathway Could Prevent Glioblastoma Comeback

New Money Scarce, so ITS Founders Chip in $13.4M

Icahn Makes Move as Genzyme Looks for Good News in 2010

White House Health Bill Adopts 12 Years for FOBs

NIH Stem Cell Definition Change 'Hugely Important'

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

mRNA vaccines are composed of messenger RNA encapsulated in lipid nanoparticles

mRNA flu vaccine can activate broad germinal center response

BioWorld

On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...

UTRN gene involved in arthrogryposis, study finds

BioWorld Science

Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...